Review shows median age of 21 years, involvement of five organ systems, and presentation four weeks after COVID-19<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Sept. 30, 2021 (HealthDay News) — Multisystem inflammatory syndrome in adults (MIS-A) presents about four weeks postacute COVID-19 with heterogeneous clinical symptoms, according to research published online Sept. 22 in JAMA Network Open<\/em>.<\/p>\n Pragna Patel, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues conducted a systematic review to identify reports of MIS-A either in the literature or from the U.S. Centers for Disease Control and Prevention surveillance system.<\/p>\n The researchers identified 221 patients with MIS-A (median age, 21 years; 70 percent men). Just over one-third of cases (36 percent) were non-Hispanic Black individuals, and 58 percent had no underlying comorbidity. More than two-thirds (68 percent) noted a previous symptomatic COVID-19-like illness a median of 28 days previously. Most common presentations included fever (96 percent), hypotension (60 percent), cardiac dysfunction (54 percent), shortness of breath (52 percent), and diarrhea (52 percent). Cases had a median of five organ systems involved and had a median hospital stay of eight days. More than half of cases (57 percent) were admitted to the intensive care unit, with 47 percent requiring respiratory support and 7 percent dying. The majority of patients (90 percent) had elevated markers of coagulopathy and\/or inflammation and a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic finding (72 percent).<\/p>\n “It is important for the clinical and public health community to suspect and identify MIS-A, a delayed immunologic response to SARS-CoV-2 infection in adults with hyperinflammation, by exercising clinical acumen and considering empirical treatment to reduce related morbidity and mortality,” the authors write.<\/p>\n